Servier agreed to acquire Day One Biopharmaceuticals for roughly $2.5 billion in cash, a deal that gives the French pharma company Ojemda (tovorafenib) — an FDA‑approved therapy for pediatric low‑grade glioma — and a pipeline of targeted oncology programs. Servier said the acquisition will strengthen its rare oncology portfolio and align with its 2030 strategic priorities. Day One’s Ojemda generated roughly $155 million in 2025 sales; Servier will fund the transaction with a mix of cash and investments. Company executives highlighted synergies with Servier’s existing brain‑tumor assets, notably Voranigo, and said the deal adds R&D assets in pediatric and adult solid tumors. Deal terms include a 68% premium to Day One’s prior close and an expected close in the second quarter. The acquisition signals continued industry appetite for commercial‑stage rare oncology assets with near‑term revenue.